Trial Profile
RECOMBINANT HUMAN INSULIN-LIKE GROWTH FACTOR-1 (rhIGF-1) TREATMENT OF CHILDREN AND ADOLESCENTS WITH GROWTH FAILURE ASSOCIATED WITH PRIMARY IGF-1 DEFICIENCY: AN OPEN-LABEL, MULTI-CENTER, EXTENSION STUDY
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 15 Aug 2020
Price :
$35
*
At a glance
- Drugs Mecasermin (Primary)
- Indications Short stature
- Focus Therapeutic Use
- Sponsors Ipsen
- 21 Oct 2013 New trial record